Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Allegion PLC (ALLE) vs BridgeBio Pharma Inc (BBIO) Price & Performance

Allegion PLCTrade
BridgeBio Pharma IncTrade

Price performance (Past 24H)

Key statistics

Allegion PLC vs BridgeBio Pharma Inc — how do they compare? Allegion PLC trades at $166.26 (market cap $14.32B), while BridgeBio Pharma Inc trades at $84.57 (market cap $16.36B). The key difference: Allegion PLC and BridgeBio Pharma Inc are close in size by market cap, and Allegion PLC pays a 1.26% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.

ALLEBBIO
Market Cap
$14.32B$16.36B
Sector
IndustrialsHealth
52-Week High
$179.77$90.17
52-Week Low
$125.65$47.29
Enterprise Value
$16.03B$18.14B
Dividend Yield
1.26%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Allegion PLC

Allegion (ALLE) trades at $165.53, down 2.02% today, near its consensus price target of $156. The stock shows bullish technical momentum with strong moving averages, though RSI levels suggest potential overbought conditions. Fundamentally, the company reported robust Q2 2026 results with EPS of $2.40 beating estimates and revenue growth of nearly 13% year-over-year, driven by strength in its Americas segment. It maintains solid profitability with a net income margin of 15.36% and ROE of 33.73%.

The outlook is positive, supported by raised full-year guidance and institutional buying, but risks include high valuation multiples and reliance on Americas market growth. Analyst sentiment is mixed with a 'Hold' consensus, indicating cautious optimism amid strong operational performance.

BridgeBio Pharma Inc

BridgeBio Pharma (BBIO) trades at $84.67, up 0.22% today, with a bullish technical signal and strong analyst consensus. Despite missing Q2 2026 EPS estimates with a loss of $0.78 per share, revenue beat expectations as Attruby sales surged 311% year-over-year. The company maintains a high gross margin of 94.44% but reports negative net income and cash flow from operations, reflecting its growth investment phase.

The outlook is optimistic due to multiple late-stage pipeline catalysts, including three potential product launches by mid-2027 and an FDA decision on encaleret by May 2027. Risks include sustained cash burn, high debt of $1.72 billion, and clinical trial execution. The consensus price target of $104.56 implies significant upside if commercial execution succeeds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Allegion PLC

Allegion is a global security products company with a portfolio of leading brands, such as Schlage, von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2021, Allegion generated 68% of sales in the United States. The company mainly competes with Swedish-based Assa Abloy AB and Switzerland-based Dormakaba.

Read more on ALLE

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Read more on BBIO